Navigation Links
Uroplasty to Present at the 24th Annual ROTH Conference
Date:3/5/2012

MINNEAPOLIS, March 5, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 24th Annual ROTH Conference at 5:30 PM PT on Monday, March 12, 2012 at The Ritz Carlton Laguna Niguel in Dana Point, CA..

Attendance at the conference is by invitation only.  A live audio webcast of the presentation will be broadcast via the Internet.  Those interested in listening to the webcast may access it at http://wsw.com/webcast/roth26/upi/ or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Chris Gale (Media), 646.201.5431

 

 

 


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
2. Uroplasty Reports Third Quarter of Fiscal 2012 Financial Results
3. Uroplasty to Issue Third Quarter 2012 Financial Results on January 26, 2012
4. Uroplasty to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical Device Conference
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
7. Uroplasty to Issue Second Quarter 2012 Financial Results on October 27, 2011
8. Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference
9. Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012
10. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
11. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Liver Cirrhosis Drugs Price Analysis and Strategies ... Cirrhosis market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Liver Cirrhosis ...
(Date:2/21/2017)... and Markets has announced the addition of the "Rosacea Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Rosacea ... market? What are the unit prices and annual treatment ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Anthrax Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are the ... positioned in the Global Anthrax market? What are the ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... 2017 , ... Support of value-based care models requires collaboration across all facets ... industry solutions, Fogo Data Centers announces the launch of the Fogo Partner Community™. , ... one in which all systems work well, work together, and work together well. ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... of technology-enabled clinical trial solutions, today announced the further expansion of its ... applications they can leverage as part of Bioclinica’s extensive and growing eHealth ...
(Date:2/21/2017)... ... February 21, 2017 , ... Atlanta-based Jvion, ... analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to date, received ... giants including Accenture, GE Ventures, and Software AG , will bring top ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... chronically untreated despite the medical, mental health, and financial consequences of inaction. On ... to take action if they have concerns about their hearing. , Effective treatment ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... protein espresso drinks, announced its products are now available for purchase on RonnieColemanNutrition.com, ... Drink Mix has become popular among health-conscious consumers who love coffee but are ...
Breaking Medicine News(10 mins):